Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0ARIWN
ADC Name	CMD-193
Synonyms	Hu3S193-CM; Hu3S193-CalichDMH; CMD 193; CD193 Click to Show/Hide
Organization	Wyeth AB; Pfizer Inc.
Drug Status	Terminated in phase 1
Indication	In total 1 Indication(s) Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Terminated in phase 1
Structure
	3D MOL	2D MOL
Antibody Name	Anti-Lewis-Y mAb G193		Antibody Info
Antigen Name	Lewis Y		Antigen Info
Payload Name	N-acetyl-gamma-calicheamicin		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	AcButDMH		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Ozogamicin
Puchem SID	135291142 , 160671752 , 160687737
ChEBI ID	CHEMBL2109504

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Complete Remission (CR)	NCT00293215	Phase 1	Biodistribution study of cmd-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Undisclosed	NCT00257881	Phase 1	Phase 1 biodistribution study of 111-indium-CMD-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Undisclosed	NCT00161642	Phase 1	Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 99	%	NCI-N87 cells	Gastric tubular adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Complete Remission (CR)	0.00%
Patients Enrolled	Patients with advanced tumours expressing the Lewis-Y antigen.
Administration Dosage	111-In-CMD-193 iv then 1.00 mg/m^2, 2.60 mg/m^2 iv of CMD-193.
*Related Clinical Trial*
NCT Number	NCT00293215	Clinical Status	Phase 1
Clinical Description	Biodistribution study of cmd-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Experiment 2 Reporting the Activity Date of This ADC				[2]
Patients Enrolled	Patients with advanced malignant tumors.
Administration Dosage	CMD-193 iv.
*Related Clinical Trial*
NCT Number	NCT00257881	Clinical Status	Phase 1
Clinical Description	Phase 1 biodistribution study of 111-indium-CMD-193 in patients with advanced tumours expressing the LEWIS-Y antigen.
Experiment 3 Reporting the Activity Date of This ADC				[3]
Patients Enrolled	Patients with advanced malignant tumors.
Administration Dosage	CMD-193 iv.
*Related Clinical Trial*
NCT Number	NCT00161642	Clinical Status	Phase 1
Clinical Description	Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[4]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.00% (Day 100)	Positive Lewis-Y expression (Lewis-Y +++/++)
Method Description	hu3S193-CalichDMH (4 ug) induces efficient tumor cell killing in cell line-derived models of PV-1 cells with CD28 expression.
In Vivo Model	N193 CDX model
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

References

Ref 1	Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
Ref 2	Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Ref 3	A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
Ref 4	Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin Cancer Res. 2004 Jul 1;10(13):4538-49. doi: 10.1158/1078-0432.CCR-04-0037.